23andMe lays off 40% of its workforce, ends therapeutics division
23andMe is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
23andMe is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
